New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Editas Medicine, Inc.

Contributing Author

Recent Articles by Editas Medicine, Inc.

Sep-02	Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate EDIT GlobeNewswire
Aug-28	Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate EDIT GlobeNewswire
Aug-27	Editas Medicine to Participate in Upcoming Investor Conferences EDIT GlobeNewswire
Aug-12	Editas Medicine Announces Second Quarter 2025 Results and Business Updates EDIT GlobeNewswire
Jun-12	Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June EDIT GlobeNewswire
May-14	Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June EDIT GlobeNewswire
May-14	Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting EDIT GlobeNewswire
May-13	Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting EDIT GlobeNewswire
May-12	Editas Medicine Announces First Quarter 2025 Results and Business Updates EDIT GlobeNewswire
May-12	Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board EDIT GlobeNewswire
May-05	Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May EDIT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.